Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term irinotecan. Found 12 abstracts

Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer. 2018 Feb 15;124(4):688-97.   PMCID: PMC6226304
El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2015 Nov 09;16(12):1726-37.
El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2015 Jan;16(12):1726-37.   PMCID: PMC4847814
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Rectal Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):838-81.   PMCID: not NIH funded
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang CF, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). JOURNAL OF CLINICAL ONCOLOGY. 2006 Mar;24(9):1395-403.
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clinical Cancer Research. 2005 Aug;11(15):5342-6.
Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2004 Jun;53(6):513-8.
de Jongh FE, Gallo JM, Shen MY, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemotherapy and Pharmacology. 2004 Aug;54(2):105-12.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term irinotecan

irinotecan chemotherapy oxaliplatin NCCN Clinical Practice Guidelines molecular profiling colorectal adjuvant chemotherapy colorectal cancer growth-factor receptor PLUS CISPLATIN metastasis neoplasm staging Topo1 Braf fluorouracil plus leucovorin high-dose neoplasm recurrence 5-fluorouracil Her2 RANDOMIZED-TRIAL phase-i precision medicine Tp53 prognostic factors Cox2 Ercc1 bevacizumab peritoneal cancer Kras thymidylate synthase surgery long-term survival c-MET Apc angiogenesis therapy FLUOROURACIL FAILURE genetics medulloblastoma average-risk medulloblastoma gene-expression controlled-trial Neoplasm Metastasis unchanged cisplatin pharmacodynamics Male ADVANCED SOLID TUMORS ADVANCED ESOPHAGOGASTRIC CANCER refractory disposition Colorectal cancer intrahepatic infusion GASTROESOPHAGEAL ADENOCARCINOMA intraarterial floxuridine Female KeyWords Plus: nephrotoxicity paclitaxel Colorectal Neoplasms esophageal cancer gamma-knife surgery multicenter lymph-node micrometastases spinal tumors High-Throughput Nucleotide Sequencing temozolomide plus cetuximab recurrent malignant glioma phase I dose-escalation unresectable liver metastases carcinoma estramustine escalation predictive factors brain tumor astrocytoma phase-iii trial Lung Neoplasms advanced solid tumors Fluorescence In Situ Hybridization colorectal liver metastases biweekly cetuximab metabolism ADVANCED GASTRIC-CANCER docetaxel anaplastic astrocytoma randomized Mutation rectal neoplasms NCCN Guidelines fluorouracil Oncology PTEN (JNCCN 2011 adenocarcinoma DNA TOPOISOMERASE-I platinum Adult metastatic breast-cancer dexamethasone design oral topotecan oxaliplatin-based Gene Amplification 9:352-400) circumferential resection margin mixture-models Gene Expression Profiling Middle Aged iii toxicity ADJUVANT CHEMOTHERAPY glioblastoma 2-STAGE DESIGNS intravenous cisplatin phase-ii trial pathology refractory prostate-cancer colon-cancer radiotherapy plus concomitant pharmacokinetics Type II DNA Topoisomerases RECEPTOR clinical-trials targeted therapy pathological complete response liver metastases leucovorin secondary Aged Peritoneal Neoplasms THERAPY Neoplasm Staging spinal-cord compression adjuvant radiotherapy platinum-based farnesyltransferase inhibitor fluorouracil-based chemotherapy advanced colorectal-cancer DOSING REGIMENS preoperative pelvic chemoradiotherapy GROWTH-FACTOR Immunohistochemistry METASTATIC COLORECTAL-CANCER metastatic colorectal-cancer R115777 prospective randomized-trial Tumor Biomarkers total mesorectal excision lymph-node metastases
Last updated on Wednesday, February 05, 2020